INTRODUCTION

EXPERIMENTAL
Yeast two-hybrid screen
A human Erythroleukaemia Matchmaker cDNA library prepared from K562 cells in pACT2 was obtained from Clontech and amplified once before screening. The cDNA encoding human PRH (HPRH) was kindly given to us by Dr G. Manfioletti (University of Trieste) as a pBluesScript clone (pBSK-HPRH) [14] . To create pAS2-1-HPRH (1-271) an EcoRI fragment carrying the human PRH cDNA was inserted into the EcoRI site of pAS2-1 (Clontech). To create pAS2-1-PRH N1-98 an EcoRI-StuI fragment from pBSK-HPRH encoding the N-terminal 132 amino acids of PRH was ligated between the EcoRI and SmaI sites of pAS2-1. In each construct the PRH coding sequence was placed in frame with the GAL4 DBD by inserting an oligonucleotide 5' C ATG CAG TAC CCG CAC CCC 3' between the EcoRI site and the internal SmaI site in the HPRH cDNA. To create pAS2-1-PRH N1-98, pAS2-1-PRH N1-132 was digested with BamHI and partially digested with ApaI. An ApaI-BamHI oligonucleotide (5' CGCCGCGCCCACG 3') was then ligated between the ApaI site located at amino acid 98 within the PRH amino acid sequence and the unique BamHI site in the vector pAS2-1. The yeast two-hybrid screen was carried out in yeast strain CG1945 essentially as described by Fields and Song [28] and the Clontech manual.
Bacterial expression plasmids
The plasmids pTrc-His-PRH 1-277 and pTrc-His-PRHC 137-277 express full-length avian PRH and a truncated PRH construct, respectively and have been described previously [18, 29] . A GST-tagged chicken PRH N-terminus (GST-PRH N1-141 ) expression vector was created by cloning the DNA sequence encoding the avian PRH N-terminus (amino acids 1-141), as a SalI-SpeI fragment into pGEX20T which had been cut with XhoI and SpeI, creating pGEX20T-PRH N1-141 . pGEX20T is a derivative of pGEX2T (Pharmacia) and contains unique XhoI and SpeI restriction sites in the polylinker downstream of the GST moiety. The GSTtagged human PRH N-terminus expression vector pGEX-HPRH N1-132 was a gift from Dr. G.
Manfioletti (University of Trieste). Briefly, DNA sequences encoding the human PRH Nterminus (amino acids 1-132) were cloned as an EcoRI fragment into pGEX3X (Pharmacia).
The DNA sequence of these plasmids and the plasmids described below were verified by DNA sequencing.
Tris pH 8.0, 50mM NaCl, 1mM MgCl 2 , 1mM dithiothreitol, 80ng/ml poly(dI.dC)(dI.dC), 0.5µg/µl bovine serum albumin, and 10% glycerol. After 30 minutes at 4ºC, the free and bound DNA were resolved on 6% non-denaturing polyacrylamide gels run in 0.5xTBE. The free and bound labelled DNA was then visualised and quantified using a PhosphorImager with Molecular Dynamics ImageQuant software (version 3.3). The apparent equilibrium constant, K eq(apparent) , was obtained using the equation below and Grafit4 software:
[ When [DNA]<<K eq , the apparent equilibrium constant is equal to the protein concentration at half maximum DNA binding. All experiments were repeated three times.
Mammalian expression plasmids and reporter plasmids
The pTK, and pTK-Gal and pSV-lacZ reporter plasmids have been described previously [18] . The pSV-lacZ reporter is available from Promega. pMUG1-Myc-PRH is a mammalian expression vector that contains a Myc9E10-tagged human PRH cDNA under the control of the CMV promoter [27] . pMUG1-GAL4-HC8 is a mammalian expression vector that contains the HC8 cDNA, obtained from the yeast plasmid pACT2-HC8, in frame with an SV40 nuclear localisation signal (NLS) and the GAL4 DBD. Expression of the GAL4-HC8 fusion protein is under the control of the CMV promoter. pMUG1-GAL4-HC8 was constructed by inserting an EcoRI-XhoI fragment obtained from pACT2-HC8 between the unique EcoRI and SalI sites of pMUG1 [27] . The EcoRI-XhoI fragment contains the HC8 cDNA and 52bp of untranslated sequence 5' to the HC8 cDNA. Subsequently an oligonucleotide encoding the SV40 nuclear localisation signal (NLS) [32] 5' AATTGCTCCTCCTAAAAAGAAGAGGAAGGG 3' was inserted into the unique EcoRI site and finally a BamHI PCR fragment encoding the GAL4 DBD (amino acids 1-147) was cloned into the unique BamHI site in pMUG1. The resulting GAL4-HC8 fusion protein thus carries the SV40 NLS between the GAL4 DBD and the HC8 coding sequence. The DNA sequence of this plasmid and the plasmids described above were verified by DNA sequencing.
Cell culture and transient transfections
K562 cells were grown in glutamine supplemented DMEM media (Sigma) with 10% foetal calf serum (FCS) to a density of approximately 1x10 6 cells/ml. The cells were collected by centrifugation and then resuspended in media plus 10% FCS to a density of 5x10 7 cells/ml. 1x10 7 cells were transiently transfected with 5µg each of the luciferase and β-galactosidase reporter plasmids described above, and the amount of expressor plasmids indicated in the Results, by electroporation using a BIORAD Genepulser (200V, 975µF).
After electroporation the cells were rested for 10 min and then incubated overnight in 10ml of supplemented media at 37°C and 5% CO 2 . After 24 hours the cells were harvested and luciferase activity assayed using the Promega Luciferase Assay System according to the manufacturer's instructions. β-galactosidase assays were performed as an internal control for transfection efficiency. After subtraction of the background the luciferase counts were normalised against the β-galactosidase value.
Whole cell and nuclear extracts
Whole cell extract from 2 x 10 8 K562 cells was made as follows. The cell pellet was collected by centrifugation for 5 min at 1500rpm in a Centurion bench top centrifuge. The cell pellet was washed in PBS twice and then resuspended in 1ml high salt lysis buffer (500mM NaCl, 50mM Tris pH 7.5, 0.1% SDS, 0.1% NP-40). The cell suspension was drawn up and down six times through a 3 X Monojet needle (1.1x50mm, 19Gx2"), incubated on ice for 5 min, and then centrifuged at maximum speed for 5 min at 4°C in an Eppendorf microcentrifuge. Nuclear extracts were made from 3 x 10 7 K562 cells as follows. The cells were pelleted as described above. All subsequent manipulations were carried out at 4°C unless otherwise stated. The cell pellet was washed in PBS, repelleted, and then resuspended in Buffer A (20mM Tris pH7.5, 5mM MgCl 2 , 0.1mM EDTA, 1mM DTT) containing 0.05%
Triton-X-100. After 10 min on ice the nuclei were collected by centrifugation for 10 min at 5000 rpm in an Eppendorf refrigerated centrifuge. The nuclei were then washed twice in 0.5ml of Buffer A. The pellet was then resuspended in 50µl of Buffer B (20mM Tris pH7.5, 5mM MgCl 2 , 0.1mM EDTA, 1mM DTT, 400mM NaCl) and incubated on ice for 30 min.
The lysate was then centrifuged at 15,000 rpm for 30 min in an Eppendorf refrigerated centrifuge. The supernatant was snap frozen in liquid nitrogen. 3x 10 7 cells results in nuclear extract containing approximately 100µg of total protein.
Pull-downs and western blotting
Whole cell extract was added to approximately 10µg of GST-HPRH N1-132 protein or 10µg of GST protein bound to glutathione resin and the samples incubated at 4°C for two hours with tumbling. After this time the resin was collected by centrifugation, washed three times in 1ml of RIPA buffer (150mM NaCl, 50mM Tris pH 7.5, 0.1% SDS, 0.1% NP-40) and resuspended in 50µl 2X SDS loading buffer. All operations were carried out at 4°C and in the presence of protease inhibitors (Roche). After SDS-PAGE the proteins were immunoblotted onto Immobilon-P membrane. HC8 protein was detected using a mouse monoclonal anti-HC8
antibody (Affiniti) and visualised using an ECL kit (Amersham Biosciences).
Co-immunoprecipitation assays
Nuclear extract was prepared from untransfected K562 cells or cells that had been transfected with Myc-tagged human PRH. The nuclear extract was incubated with the 9E10 antiMyc mouse monoclonal antibody (SantaCruz) and 40µl of Protein G beads (Sigma) for 3 hours at 4°C. The beads were then washed three times with 1ml of RIPA buffer and resuspended in 50µl of 2X SDS loading buffer. After SDS-PAGE the proteins were immunoblotted onto Immobilon-P membrane and the HC8 protein was detected as described above. Co-immunoprecipitation experiments with endogenous proteins were carried out as described above except that whole cell extracts were used and the extracts were incubated with a mouse monoclonal HC8 antibody (Affiniti) and Protein A beads (Sigma) or Protein A beads alone. After SDS-PAGE the proteins were immunoblotted onto Immobilon-P membrane and the PRH protein was detected with a mouse polyclonal PRH antibody.
RESULTS
PRH and HC8 interact in yeast
We screened for proteins that interact with PRH using the yeast two-hybrid system To determine whether the PRH N-terminus is responsible for the interaction with HC8 we co- 
PRH interacts with intact proteasomes in vitro
The HC8 
PRH interacts with HC8 in vivo
To investigate the biological significance of the interaction between PRH and HC8 in K562 cells we first examined the expression and intracellular localisation of PRH and HC8.
We have shown previously that PRH is expressed in the K562 cell line in the nucleus [24] .
To examine the intracellular localisation of PRH and HC8 in K562 cells we used confocal laser microscopy and immunofluoresence. PRH and HC8 are both expressed in the nucleus and the cytoplasm of K562 cells however neither protein appears to localise to any particular sub-cellular structures (data not shown).
To determine whether PRH and HC8 interact in K562 cells, whole cell extract was incubated with glutathione-Sepharose beads carrying equal amounts of either GST-PRH N1-132 or GST. After extensive washing the bound proteins were separated by SDS-PAGE and probed for HC8 using a mouse monoclonal anti-HC8 antibody. Figure 3A shows that the GST-PRH N1-132 protein is able to pull-down HC8 present in K562 cells ( Figure 3A , lane 3). In contrast, the GST control protein is unable to pull-down HC8 ( Figure 3A , lane 2). These data suggest that the PRH N-terminal domain is able to interact with endogenous HC8 proteins present in these cells. To confirm this result we carried out co-immunoprecipitation assays. 
PRH can be cleaved by the proteasome in vitro
The cyclin dependent kinase inhibitor p21 WAF/CIP1 interacts directly with HC8 and the interaction is essential for the rapid ubiquitin independent degradation of the p21 protein by were added to labelled oligonucleotides carrying a PRH binding site. After 30 minutes at 4ºC, free and bound labelled DNA were separated by non-denaturing polyacrylamide gel electrophoresis and visualised using a PhosphorImager ( Figure 5A ). As can be seen from the data, the full-length PRH protein has a much lower affinity for DNA than PRHC ( Figure 5A , compare lanes 1-7 with lanes 8-14); the full length protein has an apparent equilibrium constant higher than 2µM whereas PRHC has an equilibrium constant of around 200nM.
To 
PRH is not rapidly degraded by the proteasome in K562 cells
To determine whether PRH is rapidly turned over by the proteasome in K562 cells, we examined the stability of PRH in these cells. PRH levels in K562 cell nuclear extracts were assayed by Western blotting using a mouse anti-PRH polyclonal antibody at various time points after the addition of the protein synthesis inhibitor cycloheximide. As a control an established substrate of the proteasome, namely cyclin E, was also assayed by Western blotting using an anti-cyclin E monoclonal antibody. As can be seen from the data shown in Figure 6A , both cyclin E and PRH protein levels decline with time in the presence of cycloheximide (compare lanes 1 and 4) . However, the decline in PRH levels is not rapid; the half-life of PRH in these cells appears to be greater than 8 hours. To determine whether the decline in PRH levels seen in the presence of cycloheximide is due to proteasome activity, this experiment was repeated in the presence of cycloheximide and MG132, a reversible inhibitor of the proteasome. Figure 6B shows that in the presence of both cycloheximide and MG132, PRH levels do not decline over 18 hours (compare lanes 1 and 4) . Similar results were obtained for PRH and cyclin E in the presence of the proteasomal inhibitor PSI (data not shown). Thus, inhibition of the proteasome appears to increase the stability of PRH.
Under these conditions cyclin E levels accumulate in the first 3 hours ( Figure 6B , compare lanes 1 and 2), consistent with previous work that has shown that cyclin E is rapidly turned over by the proteasome. After the initial accumulation of cyclin E, there is a slow decline in cyclin E levels, presumably by a non-proteasomal mechanism. In conclusion, PRH does not appear to be rapidly turned over by the proteasome in K562 cells. However, inhibition of the proteasome does result in some stabilisation of the protein. We did not observe the presence of truncated PRH proteins in K562 cells however our antibodies cannot detect the presence of N-terminally deleted PRH proteins and so it is possible that PRH cleavage products exist that are biologically active.
Over-expression of HC8 can repress transcription
Given that a number of proteasome subunits play a role in transcription, we next set out to investigate whether the interaction of HC8 with PRH is connected with the role of PRH as a transcriptional repressor. To this end we constructed a GAL4-HC8 fusion protein by placing the HC8 coding region in frame with the GAL4 DBD in the mammalian expression vector pMUG1. This construct was transiently transfected into K562 cells together with a reporter plasmid containing the firefly luciferase gene under the control of the minimal thymidine kinase (TK) promoter and five GAL4 binding sites (TK-Gal). In addition, we cotransfected a reporter plasmid expressing β-galactosidase as a control for transfection efficiency [18] . Figure 7A shows that GAL4-HC8 (filled circles) causes a dose-dependent repression of TK-Gal reporter activity relative to that seen in the presence of equal amounts of a plasmid expressing the GAL4 DBD (filled triangles). These data suggest that GAL4-HC8 is able bind to the GAL4 sites within this reporter and repress transcription. However, we also examined the ability of GAL4-HC8 to repress transcription from a TK reporter construct lacking GAL4 binding sites (pTK) Somewhat surprisingly GAL4-HC8 is also able to repress the activity of this reporter ( Figure 7A , empty squares). Thus HC8 is able to repress transcription from the TK promoter even when not tethered to the DNA via the GAL4 DBD.
Interestingly, over-expression of HC8 has no effect on the activity of the strong SV40
enhancer/promoter present in the β-galactosidase control reporter.
To establish whether HC8 can function as a co-repressor for PRH in transient transfection assays, we co-transfected a vector expressing full-length HC8 together with a vector expressing a GAL4 DBD-PRH N1-132 fusion protein (GAL4-PRH) and reporter plasmids described above. 
Proteasome activity is not required for transcriptional repression by PRH or HC8
HC8 plays an important role in the 20S proteasome [33,34,37] and thus the repression seen when HC8 is over-expressed might simply be a consequence of increasing the amount of functional proteasome within the cell, with the result that there is an increased turnover of RNA Polymerase II or other proteins. Alternatively, the proteolytic activity of the proteasome could be important for transcriptional repression by PRH. We therefore set out to determine whether there is a connection between proteasome activity and transcriptional repression by PRH or HC8. Transient transfection assays were performed in K562 cells in the presence of MG132. Plasmids expressing either Myc-PRH or GAL4-HC8 were transiently co-transfected into K562 cells along with the TK reporter plasmid and the control reporter plasmid. Twentyfour hours after transfection, MG132 was added directly to the growth media and the cells were left to grow for a further three hours before being harvested and assayed for luciferase and β-galactosidase activity. Under these conditions proteolytic degradation of cyclin E is completely inhibited (see Figure 7B ). In keeping with our previously published data, Myc-PRH brings about the repression of TK promoter activity; to around 20% of the unrepressed reporter activity ( Figure 7B , compare columns 1 and 2). Similarly GAL4-HC8 represses TK promoter activity. However, since in this experiment we were looking for enhanced repression in the presence of MG132, we used only 0.5µg of the GAL4-HC8 expression plasmid and the level of repression is therefore weak ( Figure 7B , compare columns 1 and 3).
The addition of MG132 has little effect on TK promoter activity and has no significant effect on transcriptional repression by PRH or HC8 ( Figure 7B , columns 4-6). We conclude that the inhibition of proteasome activity for three hours does not alter transcriptional repression by PRH or HC8. Longer incubation of transfected K562 cells with MG132 (6 hours) also failed to show any significant effects on PRH or HC8-dependent repression (data not shown).
However, 6 hour incubations with MG132 are cytotoxic to K562 cells. Avian BM2
haematopoietic cells are more tolerant to exposure to MG132. However, incubation of these cells with MG132 for 15 hours also failed to bring about any significant changes in PRH or HC8-dependent repression (data not shown). These data suggest that proteasome activity is not required for repression of the TK promoter by PRH or HC8.
DISCUSSION
Here we have demonstrated that the transcriptional repressor protein PRH and the HC8 subunit from the proteasome can interact in yeast and that this interaction occurs in the context of intact proteasomes in vitro and in mammalian haematopoietic cells. We have
shown that PRH can be degraded by the 20S proteasome in an ubiquitin independent process.
However it does not appear to be rapidly degraded by the 26S proteasome in vitro or in vivo.
PRH protein levels are stabilised in cells where proteasome activity has been inhibited for 18
hours, however there does not appear to be a rapid stabilisation of PRH protein when proteasome activity is inhibited. Moreover, we did not observe any enhanced transcriptional repression by PRH after 3, or 6 hours incubation with a proteasome inhibitor. Thus there is no significant increase in repression by PRH or PRH levels after inhibition of the proteasome. Conversely, inhibition of the proteasome does not block transcriptional repression by PRH suggesting that proteasome activity is not required for transcriptional repression by PRH. This is in line with other studies which have shown that the proteasome or proteasome subunits are important for transcription activation and transcription elongation but that proteasome activity is not required [8] .
What then is the biological significance of the interaction between PRH and HC8?
One possibility is that transcriptional repression by PRH might involve HC8 and the proteasome but not require proteasome activity. Our observations that the HC8 subunit of the proteasome can itself repress TK promoter activity and that this repression is also independent of proteasome activity, may support this idea. In addition, our findings do not rule out the possibility that PRH levels in various nuclear sub-compartments, are rapidly altered by proteasome activity. PRH interacts with both HC8 and Groucho/TLE proteins [27] in the same cells and TLE1 is associated with the Nuclear Matrix [38] . It is possible that PRH associated with TLE1 in the Nuclear Matrix might be rapidly turned over by the proteasome.
Additionally, the interaction of PRH with the proteasome may be important in regulating interactions between PRH and TLE1 or other corepressors. Another possibility is that PRH undergoes processing by the proteasome. Although PRH is not rapidly degraded by the proteasome in vitro or in vivo, PRH can undergo a limited proteasomal cleavage in vitro which results in the formation of a truncated fragment that retains DNA binding activity.
Interestingly, studies have shown that expression of a truncated PRH protein consisting of the PRH homeodomain and C-terminal domain, in haematopoietic and epidermal cells has significant effects on proliferation and differentiation [24, 39] . Although the effects observed might be dominant negative activities, it is also possible that truncated PRH proteins are produced in vivo. However, we have no evidence to suggest that truncated PRH proteins are present in cells and further experiments will be needed to investigate this possibility. 
